Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Biotech Pipeline Gets A Boost From Two Acquisitions

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck will buy the monoclonal antibody developer Abmaxis and yeast glycoengineering specialist GlycoFi.

You may also be interested in...



AbbVie Goes Boldly Into Immuno-Neurology With Alector

AbbVie agreed to pay $205m up front to biotech start-up Alector to research a portfolio of antibody targets to treat Alzheimer's and other neurodegenerative diseases by harnessing the immune system.

Merck Buys Contract Manufacturing Org Avecia To Advance Biologics Strategy

With the acquisition, Merck gains a contract manufacturing organization with specific expertise in microbial-derived biologics.

Merck Buys Contract Manufacturing Org Avecia To Advance Biologics Strategy

With the acquisition, Merck gains a contract manufacturing organization with specific expertise in microbial-derived biologics.

Related Content

Topics

UsernamePublicRestriction

Register

PS064289

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel